CXCL1 and neoplasm: Additionally, CXCL1 and CXCL2 have been shown to promote the resistance of HCC cells to sorafenib,44 whereas C-X-C motif chemokine receptor 2 inhibition induces reprogramming of the tumor immune environment that promotes immune checkpoint inhibition in MASH-HCC.45